Alteration of the K-Ras gene expression in atypical and nonatypical hyperplastic endometrium

Iranian Journal of Cancer Prevention

Volumn 6, Issue 4, 2013, Pages 209-213

  Izadi Mood, Narges ^a   Sarmadi, Soheila ^a   Rostamnasl, Behzad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Endometrial cancer; Endometrial hyperplasia; Immunohistochemistry; K ras

Indexed keywords

K RAS PROTEIN;

ADULT; ARTICLE; ATYPICAL ENDOMETRIUM HYPERPLASIA; CONTROLLED STUDY; ENDOMETRIUM HYPERPLASIA; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; K RAS GENE; NONATYPICAL ENDOMETRIUM HYPERPLASIA; PROSPECTIVE STUDY;

EID: 84888409499     PISSN: 20082401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J of Clin Oncol. 2006; 24(29):4783-4791.
2. Liu F. Molecular carcinogenesis of endometrial cancer. Taiwanese J Obstet Gynecol. 2007; 46(1):26-32.
3. Fujiwara K, Enomoto T, Fujita M, Kanda T, Fujiti S, Ito K, et al. Alternation of the K-ras and p53 genes in tamoxifen-associated endometrial carcinoma. Oncol Reports. 2008; 19:1293-1298.
4. Mutter LG. Histopathology of genetically defined endometrial precancers. Inter J Gynecol Pathol. 2000; 19(4):301-309.
5. Sammoud S, Khiari M, Semeh A, Amine L, Ines C, Amira A, et al. Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia. Appl Immunohistochem Mol Morphol. 2012; 20(2):146-152.
6. Doll A, Abdal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. The J of Steroid Biol & Molecul Biol. 2008; 108(3-5):221-229.
7. Semczuk A, Schneider-Stock R, Berbec H, Marzec B, Jakowicki JA, Roessner A. K-ras exon 2 point mutations in human endometrial cancer. Cancer Lett. 2001; 164(2):207-212.
8. Lax SF, Kendall B, Tashiro H, Siebos RJC, Ellenson LH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer. 2000; 88(4):814-824.
9. Hachisuga T, Miyakawa T, Tsjioka H, Emoto M, Kawarabayashi T. K-ras mutation in tamoxifen-related endometrial polyps. Cancer. 2003; 98(9):1890-1897.
10. Elsabah MT, Adel I. Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer. J Egypt Natl Canc Inst. 2013; 25(1):51-56.
11. Mutter GL, Ince TA, Baak JPA, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Research. 2001; 61(11):4311-4314.
12. Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia. Cancer. 2006; 106(4):804-811.
13. Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. J Clin Pathol. 1999; 52(5):257-262.
14. Athanassiaadou P, Athanassiades P, Grapsa D, Gonidi M, Athanassiaadou AM, Stamati PN, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunohistochemical study. Int J Gynecol Cancer. 2007; 17(3):697-704.
15. Ikeda T, Yoshinaga K, Suzuki A, Sakurada A, Ohmori H, Horii A. Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer. Oncol Rep. 2000; 7(3):567-570.
16. Matias-Guiu X, Catasus L, Bussagila E, Lagarda H, Garcia A, Pons C, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Human Pathol. 2001; 32(6): 569-577.
17. Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res.1991; 51(19): 5308-5314.
18. Sun H, Enomoto T, Shroyer KR, Ozaki K, Fujita M, Ueda Y, et al. Clonal analysis and mutations in the PTEN and the K-ras genes in endometrial hyperplasia. Diagn Mol Pathol. 2002; 11(4):204-211.
19. Swisher EM, Peiffer-Schneider S, Mutch DG, Herzog TJ, Rader JS, Elbendary A, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer.1999; 85(1):119-126.
20. Koul A, Willén R, Bendahl PO, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicates alternate modes of tumorigenesis. Cancer.2002; 94(9): 2369-2379.